PAR.ASX: PAR Completes Enrolment in Pivotal Phase 3

PAR Completes Enrolment in Pivotal Phase 3

Stock	Paradigm Biopharmaceuticals Ltd (PAR.ASX)
Release Time	15 Jun 2026, 9:11 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

PAR Completes Enrolment in Pivotal Phase 3 Osteoarthritis Trial

Key Points

Enrolment completed on schedule in Paradigm's pivotal Phase 3 PARA_OA_012 study
Enrolment completion removes a significant execution milestone
Interim Analysis remains on track for September 2026

Full Summary

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) has successfully completed enrolment in its pivotal Phase 3 clinical trial, PARA_OA_012, evaluating Zilosul® (injectable pentosan polysulfate sodium) for the treatment of pain associated with knee osteoarthritis. The study, which is being conducted across 65 clinical sites in Australia, the United States, Hong Kong, and Moldova, has enrolled 538 participants, exceeding the original target of 466 participants. The completion of enrolment removes a significant execution risk and positions Paradigm for upcoming clinical milestones, including an Interim Analysis expected in September 2026 and top-line Phase 3 results anticipated in Q1 CY2027. Paradigm will host an investor webinar on June 18, 2026, to provide an update on the Phase 3 clinical program and upcoming milestones.